Lower MIS Levels in Women with Breast Precancer and Cancer
Author Information
Author(s): McCoy Andrew C, Kliethermes Beth, Zhang Ke, Qin Wenyi, Sticca Robert, Bouton Michael, Sauter Edward R
Primary Institution: University of North Dakota School of Medicine
Hypothesis
MIS would decrease breast cancer risk in premenopausal women, and that MIS serum levels would be different in women with benign breast disease vs. those with precancer or cancer.
Conclusion
The study provides preliminary evidence that lower MIS levels are associated with breast cancer risk.
Supporting Evidence
- Serum from women with cancer and precancer had lower MIS levels than serum from women with benign disease.
- Thirty blood samples were collected from premenopausal women scheduled for breast biopsy.
- Participants were classified based on biopsy results into cancer, precancer, or benign groups.
Takeaway
Women with breast cancer or precancer have lower levels of a substance called MIS compared to those without these conditions.
Methodology
Blood samples were collected from premenopausal women undergoing breast biopsy, and MIS levels were measured using an ELISA kit.
Potential Biases
The study was blinded to reduce bias in sample analysis.
Limitations
The study had a limited sample size and MIS was not 100% accurate in differentiating between disease states.
Participant Demographics
Participants were premenopausal women aged 38-50 years.
Statistical Information
P-Value
0.0009
Statistical Significance
p = .0009
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website